Company Name, Ticker, Competitors, else..

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Deciphera Pharmaceuticals Inc 's

Name: Deciphera Pharmaceuticals Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

DCPH Sales vs. its Competitors Q1 2024

Comparing the current results to its competitors, Deciphera Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2024 by 34.55 % year on year, while most of its competitors have experienced contraction in revenues by -8.39 %, achieved in the same quarter.

• List of DCPH Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Deciphera Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -33.36 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -33.36 %

<< DCPH Stock Performance Comparisons

<< See the full list of DCPH competitors

Overall company Market Share Q1 2024

Due to strong revenue growth of 34.55 % in Overall company Deciphera Pharmaceuticals Inc improved its market share, to approximately 0.19 %. << More on DCPH Market Share.

*Market share is calculated based on total revenue.

DCPH's Stock Performance relative to its Competitors

Publicly Traded Peers of Deciphera Pharmaceuticals Inc

Allakos Inc
Share Performance

-72.11%

One Year

Allakos Inc

Profile

Allakos Inc's business model revolves around developing and commercializing innovative therapeutic antibodies to treat allergic and inflammatory diseases.

More about Allakos Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 29.585 mill.	$ - mill.	$ -70.854 mill.

Nuvalent Inc
Share Performance

+0.46%

30 Days

Nuvalent Inc

Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 9,751.979 mill.	$ - mill.	$ -450.074 mill.

Rhythm Pharmaceuticals Inc
Share Performance

+8.15%

One Year

Rhythm Pharmaceuticals Inc

Profile

Rhythm Pharmaceuticals Inc's business model focuses on developing and commercializing therapies for rare genetic disorders that result in unmet medical needs.

More about Rhythm Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 7,138.095 mill.	$ 239.918 mill.	$ -210.222 mill.

Chinook Therapeutics Inc
Share Performance

+3.27%

30 Days

Chinook Therapeutics Inc

Profile

Chinook Therapeutics is a biotechnology company focused on the development of precision medicines for kidney diseases and other rare disorders. Their business model revolves around identifying and targeting specific pathways involved in the progression of kidney diseases, leveraging innovative technologies and partnerships to develop novel therapies that can improve patient outcomes. By prioritizing the unmet needs in the field of kidney diseases, Chinook aims to deliver transformative treatments to patients while creating value for their stakeholders.

More about Chinook Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,891.601 mill.	$ 5.849 mill.	$ -245.654 mill.

Praxis Precision Medicines Inc
Share Performance

+17.52%

This Year

Praxis Precision Medicines Inc

Profile

Praxis Precision Medicines Inc's business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.

More about Praxis Precision Medicines Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 9,805.038 mill.	$ - mill.	$ -339.126 mill.

168 more competitors available

Sources: Deciphera Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, September 14, 2026 4:00 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Deciphera Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.